Cancer refers to a specific group of disorders that lead to abnormal cell growth within any part of the body. This growth may even spread to other body parts. Cancer is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female. Gynecological cancers include cancer in the uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle &tissue supporting the uterus.
The key factors that drive the market growth include, the high incidence of gynecological cancers, growth in the importance of targeted drug therapies, an increase in investment from government, public, &private sectors for cancer treatment, and a surge in the number of product approval for gynecological cancer drugs drive the market growth. However, the high cost of drug development and the threat of failure & adverse effects of cancer drug therapy on a patient’s body restrain this growth. The advancement of cancer drug research and the advent of personalized medicine approaches are expected to provide numerous opportunities for market growth during the forecast period.
The gynecological cancer drugs market is segmented into therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
The major companies profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.
The key factors that drive the market growth include, the high incidence of gynecological cancers, growth in the importance of targeted drug therapies, an increase in investment from government, public, &private sectors for cancer treatment, and a surge in the number of product approval for gynecological cancer drugs drive the market growth. However, the high cost of drug development and the threat of failure & adverse effects of cancer drug therapy on a patient’s body restrain this growth. The advancement of cancer drug research and the advent of personalized medicine approaches are expected to provide numerous opportunities for market growth during the forecast period.
The gynecological cancer drugs market is segmented into therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
The major companies profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pneumonia testing market analysis from 2020 to 2030 to identify the prevailing pneumonia testing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the pneumonia testing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global pneumonia testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Indication
- Cervical Cancer
- Uterine Cancer
- Ovarian Cancer
- Vaginal Vulvar Cancer
By Therapeutic Modality
- Chemotherapy
- Targeted Therapy
- Hormonal Therapy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- APOTEX INC
- ASTRAZENECA PLC
- BRISTOL-MYERS SQUIBB COMPANY
- ELI LILLY AND COMPANY
- F. HOFFMANN-LA ROCHE LTD
- GLAXOSMITHKLINE PLC
- MERCK & CO., INC
- NOVARTIS AG
- PFIZER INC
- TEVA PHARMACEUTICAL INDUSTRIES LTD
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY
CHAPTER 5: GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION
CHAPTER 6: GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION
CHAPTER 7: COMPANY LANDSCAPE
CHAPTER 8: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
According to this report titled, 'Gynecological Cancer Drugs Market,' theGynecological Cancer Drugs Market Size was valued at $11.6 billion in 2020 and is estimated to reach $21.8 billion by 2030, growing at a CAGR of 6.5% from 2021 to 2030.Cancer progresses when normal body cells transform into abnormal cells and continue to grow in an uncontrolled manner. It is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female. Gynecological cancers include cancer in the uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle &tissue supporting the uterus.
The key factors that drive the growth of the Gynecological Cancer Drugs Industry are an increase in funding of R&D in the activities of gynecological cancer drugs along with rising in the prevalence of cancer. In addition, the favorable government regulations for therapy are further going to boost the Gynecological Cancer Drugs Market Growth during the forecast period. However, the high cost involved in gene therapy along with unwanted immune responses is likely to hamper the growth of the gynecological cancer drugs market during the forecast period. Conversely, advancements in cancer drug research and the advent of personalized medicine approach are expected to provide numerous opportunities for market growth during the forecast period.
By indication, the indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. The cervical cancer segment dominated the market in 2020 and is expected to remain dominant during the forecast period, owing to a surge in the incidence of cervical cancer among all the gynecological cancers.
Depending on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The targeted therapy segment dominated the market in 2020 and is expected to remain dominant during the forecast period, owing to the increased benefits of targeted therapy over chemotherapy.
The Gynecological Cancer Drugs Industry is segmented into therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
By region, Gynecological Cancer Drugs Market Analysis is done across North America, Europe, Asia-Pacific, and LAMEA. North America has the highest Gynecological Cancer Drugs Market Share, in 2020. Owing to significant investments in research and advancements in technology, the Asia-Pacific market is estimated to reach $5654.88 million at a significant CAGR of 7.1% in 2030. The presence of a large population base, government initiatives to improve healthcare infrastructure, and an increase in healthcare expenditure are the key driving factors that boost the gynecological cancer drugs market in the region.
Key findings of the Study
- On the basis of therapeutic modality, the targeted therapy segment dominated the market in 2020 and is expected to continue this trend during the forecast period.
- On the basis of indication, the cervical cancer segment dominated the market in 2020 and is expected to continue this trend during the forecast period.
- Region-wise, North America garnered the largest revenue share in 2020. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- APOTEX INC
- ASTRAZENECA PLC
- BRISTOL-MYERS SQUIBB COMPANY
- ELI LILLY AND COMPANY
- F. HOFFMANN-LA ROCHE LTD
- GLAXOSMITHKLINE PLC
- MERCK & CO., INC
- NOVARTIS AG
- PFIZER INC
- TEVA PHARMACEUTICAL INDUSTRIES LTD
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
